Free Trial
NYSE:PFE

Pfizer (PFE) Stock Price, News & Analysis

$29.75
-0.08 (-0.27%)
(As of 09/18/2024 ET)

About Pfizer Stock (NYSE:PFE)

Key Stats

Today's Range
$29.73
$30.14
50-Day Range
$28.29
$31.38
52-Week Range
$25.20
$34.11
Volume
25.45 million shs
Average Volume
37.93 million shs
Market Capitalization
$168.58 billion
P/E Ratio
N/A
Dividend Yield
5.65%
Price Target
$34.54
Consensus Rating
Moderate Buy

Company Overview

Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up. Their success with citric acid led to the company’s expansion and other major discoveries.

World War I caused a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup.

The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion. Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries.

As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children. 2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public.

 

Pfizer Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 98th Percentile

Pfizer scored higher than 98% of companies evaluated by MarketBeat, and ranked 47th out of 1,015 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pfizer has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 6 buy ratings, 8 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Pfizer has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Pfizer's stock forecast and price target.
  • Earnings Growth

    Earnings for Pfizer are expected to grow by 7.14% in the coming year, from $2.66 to $2.85 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pfizer is -495.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pfizer is -495.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Pfizer has a PEG Ratio of 1.02. PEG Ratios around 1 indicate that a company is correctly valued.

  • Price to Book Value per Share Ratio

    Pfizer has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Pfizer's valuation and earnings.
  • Percentage of Shares Shorted

    1.15% of the outstanding shares of Pfizer have been sold short.
  • Short Interest Ratio / Days to Cover

    Pfizer has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pfizer has recently increased by 5.91%, indicating that investor sentiment is decreasing significantly.
  • Dividend Leadership

    Pfizer is a leading dividend payer. It pays a dividend yield of 5.76%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Pfizer has been increasing its dividend for 15 years.

  • Dividend Sustainability

    Based on earnings estimates, Pfizer will have a dividend payout ratio of 58.95% next year. This indicates that Pfizer will be able to sustain or increase its dividend.

  • Read more about Pfizer's dividend.
  • Percentage of Shares Shorted

    1.15% of the outstanding shares of Pfizer have been sold short.
  • Short Interest Ratio / Days to Cover

    Pfizer has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pfizer has recently increased by 5.91%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Pfizer has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 40 news articles for Pfizer this week, compared to 36 articles on an average week.
  • Search Interest

    Only 225 people have searched for PFE on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.
  • MarketBeat Follows

    Only 54 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is a decrease of -28% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pfizer insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.06% of the stock of Pfizer is held by insiders.

  • Percentage Held by Institutions

    68.36% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pfizer's insider trading history.
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Stock News Headlines

Alnylam Stock Soars 65%: Find Out What’s Behind the Gains
Alnylam Stock Soars 65%: Find Out What’s Behind the Gains (PFE)
Alnylam Pharmaceutical is on the move. In early to mid-2025, the FDA is expected to approve expanded use of a key drug.
2 Election-Proof Dividends Growing Up to 67%
How about two bold election predictions—and two payouts that will thrive regardless of the results? My first forecast: Americans will still want to ea
Kamala Harris and The Woke Progressive Nightmare
New research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election Meltdown” coming this November.
3 Bargain-Priced Growth Stocks for Fall 2024
3 Bargain-Priced Growth Stocks for Fall 2024
Investors can leverage market volatility to uncover undervalued companies with solid fundamentals and significant growth potential.
weight loss injection with measuring tape Eli Lilly
Eli Lilly’s Path to the Next Trillion Market Capitalization (PFE)
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.
Pfizer's (PFE) "Overweight" Rating Reaffirmed at Cantor Fitzgerald
See More Headlines

PFE Stock Analysis - Frequently Asked Questions

Pfizer's stock was trading at $28.79 at the start of the year. Since then, PFE shares have increased by 3.3% and is now trading at $29.75.
View the best growth stocks for 2024 here
.

Pfizer Inc. (NYSE:PFE) announced its quarterly earnings results on Tuesday, July, 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. The company's revenue was up 2.1% on a year-over-year basis.
Read the conference call transcript
.

Pfizer subsidiaries include ReViral, Arena, Trillium Therapeutics, Amplyx Pharmaceuticals, Array BioPharma, Therachon, Medivation, and others.

Top institutional investors of Pfizer include Massachusetts Financial Services Co. MA (1.27%), Legal & General Group Plc (0.82%), Bank of New York Mellon Corp (0.74%) and Dimensional Fund Advisors LP (0.59%). Insiders that own company stock include Pfizer Inc, William R Carapezzi Jr, Jennifer B Damico, Scott Gottlieb, Alexander R Mackenzie, John D Young and Douglas M Lankler.
View institutional ownership trends
.

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV) and Walt Disney (DIS).

Company Calendar

Ex-Dividend for 9/3 Dividend
7/26/2024
Last Earnings
7/30/2024
Dividend Payable
9/03/2024
Today
9/18/2024
Next Earnings (Confirmed)
10/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
71708110
Employees
88,000
Year Founded
1849

Price Target and Rating

Average Stock Price Target
$34.54
High Stock Price Target
$45.00
Low Stock Price Target
$29.00
Potential Upside/Downside
+16.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
15 Analysts

Profitability

Net Income
$2.12 billion
Pretax Margin
-7.48%

Debt

Sales & Book Value

Annual Sales
$58.50 billion
Cash Flow
$3.04 per share
Book Value
$15.81 per share

Miscellaneous

Outstanding Shares
5,666,690,000
Free Float
5,663,193,000
Market Cap
$168.58 billion
Optionable
Optionable
Beta
0.68

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 11, 2024. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

Pfizer
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Pfizer Inc.:

  • Pfizer Inc. has recently received upgraded ratings from multiple analysts, indicating strong confidence in the company's performance and potential growth.
  • Pfizer Inc.'s stock price has been showing positive momentum, trading at a favorable level of $29.01 as of today, which may present a good entry point for investors.
  • The company has a solid track record of consistently beating earnings estimates, as seen in its recent quarterly report where it surpassed expectations by $0.14 per share.
  • Pfizer Inc. has a diverse portfolio of biopharmaceutical products with a global presence, providing stability and potential for revenue growth.
  • With a positive return on equity of 8.42%, Pfizer Inc. demonstrates efficient utilization of shareholder equity to generate profits.

Pfizer
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Pfizer Inc. for these reasons:

  • Despite recent positive developments, Pfizer Inc. operates in a highly competitive industry with constant regulatory challenges and patent expirations that could impact future revenue streams.
  • The company's dividend payout ratio is currently -2,800.00%, indicating an unsustainable dividend policy that may raise concerns among income-focused investors.
  • Pfizer Inc.'s stock performance has shown volatility in the past, with fluctuations in share price that may pose risks to short-term investors.
  • Market analysts have issued a mix of ratings for Pfizer Inc., with some maintaining a neutral stance, suggesting uncertainty in the company's future performance.
  • The biopharmaceutical sector is subject to rapid technological advancements and changing market dynamics, which could impact Pfizer Inc.'s competitive position and profitability.

This page (NYSE:PFE) was last updated on 9/18/2024 by MarketBeat.com Staff
From Our Partners